TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1740212

Group type: EXPERIMENTAL
Intervention: CZB medium (supplemented with 0.11 mM ethylenediaminetetraacetic acid, 1.0 mM glutamine, 31.30 mM lactate, and 0.27 mM pyruvate)
Number of subjects: 49

Group type: COMPARATOR
Intervention: EBSS medium (supplemented with 0.45 mM pyruvate)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CZB medium
Number of subjects: 49

Group type: COMPARATOR
Intervention: EBSS medium
Number of subjects: 49
Study: 6238991

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Independent of treatment
Number of subjects: 0
Study: 30738562

Group type: EXPERIMENTAL
Intervention: Strong Hearts, Healthy Communities (SHHC) program
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (93 women)
Number of subjects: 101
Study: 30761790

Group type: EXPERIMENTAL
Intervention: NefraDoz (1 capsule three times daily for one month)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard antibacterial therapy (control group)
Number of subjects: 116
Study: 26216648

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (6000 mg day(-1) of fish oil)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (6000 mg day(-1) of soybean oil)
Number of subjects: 52
Study: 25135060

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.1 g/kg/d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 22571246

Group type: EXPERIMENTAL
Intervention: Let's Talk about Children intervention (2 meetings with parents)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Family Talk Intervention (6 to 8 meetings with parents, children, and whole family)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Baseline GSI score of patients was at the same level as psychiatric outpatient sample; at 4-month follow-up, it was at the same level as in the general population.
Number of subjects: 19
Study: 19059660

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 18354390

Group type: EXPERIMENTAL
Intervention: Inhalation of 9% CO2
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Inhalation of 17.5% CO2
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Inhalation of 35% CO2
Number of subjects: 64

Group type: COMPARATOR
Intervention: Inhalation of 0% CO2 (control)
Number of subjects: 64
Study: 16097710

Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil every other day for 7 weeks after the intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no vardenafil)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Study group (vardenafil)
Number of subjects: 60
Study: 12451366

Group type: EXPERIMENTAL
Intervention: 6 units of BTX‐A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12 units of BTX‐A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 18 units of BTX‐A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10612642

Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs
Number of subjects: 1560

Group type: EXPERIMENTAL
Intervention: Alprostadil-alpha-cyclodextrine
Number of subjects: 1560

Group type: EXPERIMENTAL
Intervention: Revascularisation
Number of subjects: 1560

Group type: EXPERIMENTAL
Intervention: Prior major vascular events
Number of subjects: 1560

Group type: EXPERIMENTAL
Intervention: Diabetes (cardiovascular risk factor)
Number of subjects: 1560

Group type: EXPERIMENTAL
Intervention: Tissue loss
Number of subjects: 1560

Group type: EXPERIMENTAL
Intervention: Ankle pressure (unmeasurable)
Number of subjects: 1560

Group type: COMPARATOR
Intervention: Revascularisation (compared to surgery deemed unnecessary)
Number of subjects: 1560
Study: 7500239

Group type: EXPERIMENTAL
Intervention: ePTFE interproximal membranes in combination with decalcified freeze‐dried bone (DFDBA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: ePTFE interproximal membranes alone (control)
Number of subjects: 11
Study: 8257542

Group type: EXPERIMENTAL
Intervention: Mycoprotein
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chicken
Number of subjects: 0
Study: 2878134

Group type: EXPERIMENTAL
Intervention: Epidural morphine 5 mg in 5 ml of water
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 150 micrograms in 5 ml of saline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine 0.3 mg in 5 ml of saline
Number of subjects: 15

Group type: COMPARATOR
Intervention: No injection
Number of subjects: 15
Study: 29326420

Group type: EXPERIMENTAL
Intervention: 20 °C exposure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 25 °C exposure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 27 °C exposure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Temperature decrease
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fasting irisin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Postprandial RQ at 20 °C
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin to glucose ratios at 20 °C
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Temperature difference (27 °C vs 20 °C)
Number of subjects: 20
Study: 27318524

Group type: EXPERIMENTAL
Intervention: Copper alloy surfaces
Number of subjects: 515

Group type: COMPARATOR
Intervention: Non-copper surfaces
Number of subjects: 515
Study: 25823765

Group type: EXPERIMENTAL
Intervention: Lead-free radiation-attenuating drape (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham drapes (n=50)
Number of subjects: 100
Study: 23437807

Group type: EXPERIMENTAL
Intervention: Cryoablation for AVNRT
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Cryoablation for nonsustained AVNRT
Number of subjects: 83
Study: 22051332

Group type: EXPERIMENTAL
Intervention: Exogenous B-type natriuretic peptide (BNP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Volume expansion (VE) with normal saline (0.25 ml/kg/min for 60 min)
Number of subjects: 58
Study: 19194157

Group type: EXPERIMENTAL
Intervention: Midazolam (20 and 40 ng/ml)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Propofol (0.45 and 0.9 microg/ml)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.25 and 0.4 ng/ml)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Thiopental (1.5 and 3 microg/ml)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 16357331

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily
Number of subjects: 770

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 770
Study: 15070633

Group type: EXPERIMENTAL
Intervention: Three days of oral amoxicillin 31‐54 mg/kg/day in three divided doses
Number of subjects: 2188

Group type: EXPERIMENTAL
Intervention: Five days of oral amoxicillin 31‐54 mg/kg/day in three divided doses
Number of subjects: 2188
Study: 11295017

Group type: EXPERIMENTAL
Intervention: Generic foam seat cushion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Pressure‐reducing seat cushion
Number of subjects: 32
Study: 9651060

Group type: EXPERIMENTAL
Intervention: Conventional or digitally subtracted selective angiograms
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Conventionally and digitally subtracted aortic arch injection angiograms
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Intravenous digital subtraction angiograms
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Good quality angiograms
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Poor quality angiograms
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Assessment of plaque surface morphology
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Selective angiograms with good quality visualization
Number of subjects: 1001
Study: 8062314

Group type: EXPERIMENTAL
Intervention: carteolol (15 mg/d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: atenolol (50 mg/d)
Number of subjects: 15
Study: 3190508

Group type: EXPERIMENTAL
Intervention: Rhubarb pie
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Steamed rice
Number of subjects: 16

Group type: COMPARATOR
Intervention: Citric acid (52, 156, and 260 mmol/l)
Number of subjects: 16
Study: 28741894

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 126

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 126
Study: 26547101

Group type: EXPERIMENTAL
Intervention: Mammography and ultrasonography (intervention group)
Number of subjects: 72998

Group type: COMPARATOR
Intervention: Mammography alone (control group)
Number of subjects: 72998
Study: 24919603

Group type: EXPERIMENTAL
Intervention: Insulin glargine with stepwise addition of up to three insulin glulisine injections (G + 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice-daily premixed 70/30 insulin protamine-aspart/aspart (PM-2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine with up to one insulin glulisine injection (G + 1)
Number of subjects: 0
Study: 22889675

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20109213

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg PO once daily for 5 days, repeated every 8 weeks for a total of six courses
Number of subjects: 1149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1149
Study: 18524823

Group type: EXPERIMENTAL
Intervention: DNA priming followed by Ad5 boosting
Number of subjects: 120

Group type: COMPARATOR
Intervention: Homologous Ad5/Ad5 prime-boost regimen
Number of subjects: 120
Study: 15904728

Group type: EXPERIMENTAL
Intervention: Remifentanil-midazolam
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sufentanil-midazolam
Number of subjects: 41
Study: 14728392

Group type: EXPERIMENTAL
Intervention: Electronic patient diary (ED)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper diary (PD)
Number of subjects: 0
Study: 10103325

Group type: EXPERIMENTAL
Intervention: Intervention period (January 1998 - March 1998) with price information provided to physicians.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Washout period (April 1998) after intervention.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control period (September 1997 - December 1997) without price information.
Number of subjects: 0
Study: 2702680

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: BCG + DTIC
Number of subjects: 668
Study: 410230

Group type: EXPERIMENTAL
Intervention: 2% disodium cromoglycate (DSCG) nasal spray
Number of subjects: 24
Study: 30617786

Group type: EXPERIMENTAL
Intervention: Repeated DOMS Group (RD Group)
Number of subjects: 23
Study: 29653492

Group type: EXPERIMENTAL
Intervention: Visual Arts Education (VAE)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (slide shows, discussions about art, and painting)
Number of subjects: 26
Study: 28117536

Group type: EXPERIMENTAL
Intervention: Primary prevention ICD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implantable loop recorder (ILR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life assessed by Minnesota Living with Heart Failure Questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heart failure related hospitalizations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-utility analysis
Number of subjects: 0
Study: 24839145

Group type: EXPERIMENTAL
Intervention: Treatment for overweight, Class I, and Class II obese women
Number of subjects: 958

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 958
Study: 24256551

Group type: EXPERIMENTAL
Intervention: Prediction model for 10-year patient survival after baseline developed through multivariate Cox regression analysis.
Number of subjects: 13868

Group type: EXPERIMENTAL
Intervention: Inclusion of registration on the transplant waiting list as a predictor.
Number of subjects: 13868
Study: 21225104

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dipyrone (15 mg/kg)
Number of subjects: 80
Study: 20011884

Group type: EXPERIMENTAL
Intervention: Physiotherapeutic instructions regarding surgery procedures and ventilatory exercises
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no physiotherapeutic instructions)
Number of subjects: 51
Study: 17535290

Group type: EXPERIMENTAL
Intervention: ANALOGUE (optimized analogue therapy; lispro/glargine)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CSII (continuous subcutaneous insulin infusion therapy; lispro)
Number of subjects: 21

Group type: COMPARATOR
Intervention: EDUCATION (re-education with relaxation of blood glucose targets on existing conventional insulin regimen)
Number of subjects: 21
Study: 15471655

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 134

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Radiotherapy only (not pre-treated with chemotherapy)
Number of subjects: 134
Study: 11598580

Group type: EXPERIMENTAL
Intervention: Intracanal corticosteroid-antibiotic compound
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 9649455

Group type: EXPERIMENTAL
Intervention: Oral beclomethasone dipropionate (8 mg/day) plus prednisone (1 mg.kg‐1.day‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo capsules plus prednisone (1 mg.kg‐1.day‐1)
Number of subjects: 60
Study: 7979170

Group type: EXPERIMENTAL
Intervention: Vitamin C intake of 20 mg/kg or more
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin C intake above 20 mg/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin C intake of 8 mg/kg/day
Number of subjects: 0
Study: 2898368

Group type: EXPERIMENTAL
Intervention: Fenoterol (0.2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salbutamol (2 x 0.1 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terbutaline (2 x 0.25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (maximal mean plasma concentration 14.9 +/- 2.2 mg l-1) after placebo inhalation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of theophylline and fenoterol
Number of subjects: 0
Study: 217218

Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31232823

Group type: EXPERIMENTAL
Intervention: Flower petal training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Chicken leg femoral artery training
Number of subjects: 16
Study: 27411333

Group type: EXPERIMENTAL
Intervention: Remifentanil 2.0 ng/ml
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Remifentanil 3.0 ng/ml
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Remifentanil 4.0 ng/ml
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Noxious stimuli (laryngoscopy/intubation, tetanic, incision)
Number of subjects: 34
Study: 25442112

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.4 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 24045005

Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention (alternating condition, n=132)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention (summative condition, n=181)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention (both conditions combined)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Control group (n=135)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Alternating condition
Number of subjects: 448
Study: 22487920

Group type: EXPERIMENTAL
Intervention: Local EMLA cream preoperatively (Group I, N=15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No preoperative preparation (Group II, N=15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo group (Group III, N=15)
Number of subjects: 45
Study: 20500126

Group type: EXPERIMENTAL
Intervention: Caffeine (80 mg, 3x/day for 6 days followed by a challenge dose of 250 mg)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 17683327

Group type: EXPERIMENTAL
Intervention: Quartz tungsten halogen curing light
Number of subjects: 70

Group type: COMPARATOR
Intervention: Plasma arc curing light
Number of subjects: 70
Study: 16219950

Group type: EXPERIMENTAL
Intervention: Combination therapy of orbital irradiation and systemic steroids (SRT group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Systemic steroids alone (ST group)
Number of subjects: 16
Study: 12153596

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) 6.5 mg/m2
Number of subjects: 19

Group type: COMPARATOR
Intervention: Prednisolone (Pred) 40 mg/m2
Number of subjects: 19
Study: 10206611

Group type: EXPERIMENTAL
Intervention: Intersulcate line measurement method
Number of subjects: 36

Group type: COMPARATOR
Intervention: Line of eburnation measurement method
Number of subjects: 36
Study: 7628186

Group type: EXPERIMENTAL
Intervention: 20 mg prednisone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2699147

Group type: EXPERIMENTAL
Intervention: Combination of five markers (CEA, SCC, TPA, CA 50, ferritin)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SCC marker
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Five markers (CEA, SCC, TPA, CA 50, ferritin)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Follow-up on 21 randomized patients
Number of subjects: 54
Study: 91778

Group type: EXPERIMENTAL
Intervention: DDAVP (1-desamino-8-D-arginine vasopressin)
Number of subjects: 4
Study: 30701435

Group type: EXPERIMENTAL
Intervention: SST with unstructured play
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SST with semi-structured play
Number of subjects: 45

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 45
Study: 27856020

Group type: EXPERIMENTAL
Intervention: Ultrasonography-assisted lumbar puncture
Number of subjects: 128

Group type: COMPARATOR
Intervention: Traditional lumbar puncture
Number of subjects: 128
Study: 26551181

Group type: COMPARATOR
Intervention: Planned cesarean delivery
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: Planned vaginal delivery
Number of subjects: 2603
Study: 22760005

Group type: EXPERIMENTAL
Intervention: Granulocyte/monocyte apheresis (GMA)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Sham apheresis
Number of subjects: 235
Study: 21204103

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 0
Study: 19138505

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600mg o.d.
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500microg b.i.d.
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 16962156

Group type: EXPERIMENTAL
Intervention: Combined cues
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single cues
Number of subjects: 0
Study: 15293490

Group type: EXPERIMENTAL
Intervention: Balance training and vestibular rehabilitation in group sessions twice a week for six weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42
Study: 11430325

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1 mg/kg body weight)
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 1202
Study: 9429379

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Homologous blood transfusion
Number of subjects: 50
Study: 8504634

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (4 x 5 g of creatine plus 1 g of glucose/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (4 x 6 g of glucose/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3114788

Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oxazepam 15 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oxazepam 30 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30277951

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no PRF)
Number of subjects: 20
Study: 27779482

Group type: EXPERIMENTAL
Intervention: 0.5 mg of alprazolam orally one hour before the procedure
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25404102

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (200 µg daily for 8 weeks, then 200 µg on alternate days for 16 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline nasal spray (control)
Number of subjects: 100
Study: 23239871

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) applied during the second trial to heighten sympathetic nerve activity.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with no alteration in sympathetic nerve activity between trials.
Number of subjects: 0
Study: 20083626

Group type: EXPERIMENTAL
Intervention: Pulsed infusions of levosimendan (6 h administration at 0.2 microg/kg/min every 2 weeks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pulsed infusions of levosimendan
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 120
Study: 18456697

Group type: EXPERIMENTAL
Intervention: Gastrostomy placement
Number of subjects: 76
Study: 16130187

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 20
Study: 12151930

Group type: EXPERIMENTAL
Intervention: NOx.5 l (oxygen-nitrous oxide, MFA after 10 min high fresh gas flow)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ox.5 l (oxygen, MFA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ox1 l (oxygen, LFA)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: NOx1 l (oxygen-nitrous oxide, LFA after 10 min high fresh gas flow)
Number of subjects: 56